194 related articles for article (PubMed ID: 29374820)
1. Paradigm shift in theranostics of neuroendocrine tumors: conceptual horizons of nanotechnology in nuclear medicine.
Arora G; Bandopadhyaya G
Ann Nucl Med; 2018 Apr; 32(3):151-164. PubMed ID: 29374820
[TBL] [Abstract][Full Text] [Related]
2. [Theranostics in 2020: Neuroendocrine tumors].
Sipka G; Besenyi Z; Farkas I; Pávics L
Magy Onkol; 2020 Jun; 64(2):119-130. PubMed ID: 32520005
[TBL] [Abstract][Full Text] [Related]
3. An Impressive Approach in Nuclear Medicine: Theranostics.
Vahidfar N; Eppard E; Farzanehfar S; Yordanova A; Fallahpoor M; Ahmadzadehfar H
PET Clin; 2021 Jul; 16(3):327-340. PubMed ID: 34053577
[TBL] [Abstract][Full Text] [Related]
4. Radioligand Theranostics in the Management of Neuroendocrine Tumors.
Harris AG; Vinik AI; OʼDorisio TM; OʼDorisio MS
Pancreas; 2020; 49(5):599-603. PubMed ID: 32433395
[No Abstract] [Full Text] [Related]
5. Molecular Imaging and Theranostics in Pancreatic Neuroendocrine Tumours: From a Luminous Present to an Even Brighter Future.
Paola M; Mansi L
Curr Radiopharm; 2019; 12(2):93-95. PubMed ID: 31362647
[No Abstract] [Full Text] [Related]
6. Diagnosis and therapy of neuroendocrine tumours.
Bombardieri E; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):1-2. PubMed ID: 20168281
[No Abstract] [Full Text] [Related]
7. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
8. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
Duan H; Iagaru A; Aparici CM
Nanotheranostics; 2022; 6(1):103-117. PubMed ID: 34976584
[TBL] [Abstract][Full Text] [Related]
9. EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumours-the consensus in a nutshell.
Kunikowska J; Ambrosini V; Herrmann K
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1276-1277. PubMed ID: 33624150
[No Abstract] [Full Text] [Related]
10. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
[TBL] [Abstract][Full Text] [Related]
11. EANM Focus 1: one small step for two men, one giant leap for a specialty.
Fanti S; Oyen WJG
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1400-1401. PubMed ID: 31016331
[No Abstract] [Full Text] [Related]
12. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostics and treatment of neuroendocrine tumors of the digestive tract in the light of the present standards].
Szczeblowska D
Pol Merkur Lekarski; 2007 May; 22(131):437-41. PubMed ID: 17679390
[TBL] [Abstract][Full Text] [Related]
14. SNM 2012 image of the year.
J Nucl Med; 2012 Oct; 53(10):23N. PubMed ID: 23028181
[No Abstract] [Full Text] [Related]
15. Nuclear Medicine Imaging of Neuroendocrine Tumors.
Brabander T; Kwekkeboom DJ; Feelders RA; Brouwers AH; Teunissen JJ
Front Horm Res; 2015; 44():73-87. PubMed ID: 26303705
[TBL] [Abstract][Full Text] [Related]
16. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Kjaer A; Knigge U
Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
[TBL] [Abstract][Full Text] [Related]
17. Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging.
Minutoli F; Laudicella R; Burger IA; Baldari S
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3041-3042. PubMed ID: 33851244
[No Abstract] [Full Text] [Related]
18. Transforming Nuclear Medicine with Nanoradiopharmaceuticals.
Roy I; Krishnan S; Kabashin AV; Zavestovskaya IN; Prasad PN
ACS Nano; 2022 Apr; 16(4):5036-5061. PubMed ID: 35294165
[TBL] [Abstract][Full Text] [Related]
19. Application of modelling and nanotechnology-based approaches: The emergence of breakthroughs in theranostics of central nervous system disorders.
Hassanzadeh P; Atyabi F; Dinarvand R
Life Sci; 2017 Aug; 182():93-103. PubMed ID: 28583367
[TBL] [Abstract][Full Text] [Related]
20. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
